aibio
Financings ·
Tenax Therapeutics agrees to $25 million private placement with RTW Investments
RTW is to buy 378,346 shares at $6.04 and pre-funded warrants for 3,760,726 shares. Tenax plans to use the money for Phase 3 trials.
TENX Tenax Therapeutics, Inc.
Tenax Therapeutics (TENX) news TENX offering news
Latest Tenax Therapeutics news
We have not published a story on Tenax Therapeutics yet. When there is news, it will appear here.
Tenax Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $32.7 million | $12.7 million |
| Net income (loss) | -$52.6 million | -$17.6 million |
| Cash from operations | -$35.8 million | -$14.8 million |
| Cash and equivalents | $97.6 million | $94.9 million |
Questions about Tenax Therapeutics
Has Tenax Therapeutics raised money recently?
Our latest story on this, dated Mar 6, 2025: "Tenax Therapeutics agrees to $25 million private placement with RTW Investments". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Tenax Therapeutics?
Tenax Therapeutics, Inc. trades under the ticker TENX on NASDAQ.
Where is Tenax Therapeutics listed?
Tenax Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Tenax Therapeutics?
The SEC Central Index Key (CIK) for Tenax Therapeutics, Inc. is 34956. Its filings are on SEC EDGAR.
How many shares does Tenax Therapeutics have outstanding?
37,423,917 shares as of 2026-07-28, per the cover page of its 10-Q filed 2026-07-31.
Which country or territory is Tenax Therapeutics listed under?
Our directory records Tenax Therapeutics, Inc. under United States.
What does Tenax Therapeutics do?
Our directory classifies Tenax Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Tenax Therapeutics?
The ISIN recorded for Tenax Therapeutics, Inc. is US88032L6056.
Does aibio.space cover Tenax Therapeutics?
aibio.space lists Tenax Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Tenax Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Tenax Therapeutics profitable?
Tenax Therapeutics, Inc. reported a net loss of $52.6 million for the fiscal year ended Dec 31, 2025, and used $35.8 million of cash in operations, per its annual report to the SEC.
How much does Tenax Therapeutics spend on research and development?
$32.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Tenax Therapeutics have?
$118.0 million in cash at Jun 30, 2026, per its 10-Q.
What is the latest Tenax Therapeutics (TENX) stock news?
Our latest story on Tenax Therapeutics, dated Mar 6, 2025: "Tenax Therapeutics agrees to $25 million private placement with RTW Investments". RTW is to buy 378,346 shares at $6.04 and pre-funded warrants for 3,760,726 shares. Tenax plans to use the money for Phase 3 trials. Source.
What is Tenax Therapeutics's market cap?
We do not publish live share prices. In its annual report, Tenax Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $23.8 million as of Jun 30, 2025.
Investor discussion: Tenax Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
- Legal
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Tenax Therapeutics, Inc.
- CIK
- 34956
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- TENX (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 101 GLEN LENNOX DRIVE, CHAPEL HILL, NC, 27517
- Phone
- 919-855-2100
- Shares outstanding
- 37,423,917 as of 2026-07-28 (10-Q filed 2026-07-31)
- Former names
- OXYGEN BIOTHERAPEUTICS, INC.; SYNTHETIC BLOOD INTERNATIONAL INC
Recent filings
Listing details
- Company
- Tenax Therapeutics, Inc.
- Ticker
- TENX
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US88032L6056
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction